Business

Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™. Mercury 1 is a 12-month safety and efficacy tria

LSGPA Invests an Additional $500,000 in MacuLogix, Inc.

HARRISBURG, Pa.–(BUSINESS WIRE)–#AMD–The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) announced today an additional investment of $500,000 in MacuLogix, Inc. The investment was part of a syndicate with other, unnamed investors and brings LSGPA’s total investment in the Middletown-based firm to over $2 million. MacuLogix is the developer of the AdaptDx, an automated dark adaptometer that enables eye care professionals to diagnose, monitor and treat age-related macular degeneration (AMD)

Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced three important milestones in improving access to DecisionDx®-UM, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. Palmetto GBA, the administrator of the MolDX® program that assesses molecular diagnostic technologies on behalf of the Centers for Medicare and Medicaid Services (CMS),

Global Tipiracil / Trifluridine Sales, Price Analysis, & Sales Forecasts 2016-2021 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Tipiracil / Trifluridine Sales, Price Analysis, & Sales Forecast – 2017″ report has been added to Research and Markets’ offering. Find out the sales of Tipiracil / Trifluridine worldwide and by countries in North America, Europe, Japan, BRIC, and Australia. Discover the growth trends of Tipiracil / Trifluridine by countries, and also find out sales forecast until 2021. The research also provides Tipiracil / Trifluridine unit price by countries. The sales and pr

Beaver-Visitec International Acquires Vitreq

WALTHAM, Mass.–(BUSINESS WIRE)–Beaver-Visitec International (BVI), a leading global developer, manufacturer, and marketer of specialized surgical devices for the ophthalmic marketplace, announced today it has acquired Vitreq, a next-generation ophthalmic technology company. Additional terms of the transaction were not disclosed. “At Vitreq, it’s our mission to develop reliable, safe, and sophisticated tools that provide surgeons with the support and innovation necessary to perform at the high

Ocular Therapeutix™ Receives Complete Response Letter from FDA for DEXTENZA™ NDA

BEDFORD, Mass.–(BUSINESS WIRE)–Ocular TherapeutixTM, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA), regarding its resubmission of a New Drug Application (NDA) for DEXTENZA™ (dexamethasone insert) 0.4mg for the treatment of ocular pain following ophthal

Second Sight Announces Market Entry into South Korea with Two Implants and Performs Second Implant in Taiwan of Argus II Retinal Prosthesis System

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide useful vision to blind patients, today announced market entry into South Korea, implanting two patients with the Company’s Argus® II Retinal Prosthesis System (“Argus II”) in Seoul. The implants were facilitated by the country’s exclusive distribution partner, Kisantech Co., Ltd. A second patient